Welcome!

News Feed Item

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280946/Spinal-Muscular-Atrophy-SMA-Global-Clinical-Trials-Review-H2-2014.html

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014" provides data on the Spinal Muscular Atrophy (SMA) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Muscular Atrophy (SMA). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Muscular Atrophy (SMA). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Muscular Atrophy (SMA) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Muscular Atrophy (SMA) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Isis Pharmaceuticals, Inc. 32
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 32
Trophos SA 33
Clinical Trial Overview of Trophos SA 33
Westat, Inc. 34
Clinical Trial Overview of Westat, Inc. 34
Repligen Corporation 35
Clinical Trial Overview of Repligen Corporation 35
PTC Therapeutics, Inc. 36
Clinical Trial Overview of PTC Therapeutics, Inc. 36
Natera, Inc. 37
Clinical Trial Overview of Natera, Inc. 37
Hill-Rom Holdings, Inc. 38
Clinical Trial Overview of Hill-Rom Holdings, Inc. 38
GlaxoSmithKline plc 39
Clinical Trial Overview of GlaxoSmithKline plc 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of Top Institutes / Government 41
University of Utah 41
Clinical Trial Overview of University of Utah 41
National Institute of Neurological Disorders and Stroke 42
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 42
Columbia University 43
Clinical Trial Overview of Columbia University 43
Assistance Publique - Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 44
Stanford University 45
Clinical Trial Overview of Stanford University 45
All India Institute of Medical Sciences 46
Clinical Trial Overview of All India Institute of Medical Sciences 46
Nagoya University 47
Clinical Trial Overview of Nagoya University 47
JASMITT Clinical Trial Office 48
Clinical Trial Overview of JASMITT Clinical Trial Office 48
National Taiwan University Hospital 49
Clinical Trial Overview of National Taiwan University Hospital 49
University Hospital Freiburg 50
Clinical Trial Overview of University Hospital Freiburg 50
Five Key Clinical Profiles 51
Appendix 77
Abbreviations 77
Definitions 77
Research Methodology 78
Secondary Research 78
About GlobalData 79
Contact Us 79
Disclaimer 79
Source 79

List of Tables

Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2014* 32
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Trophos SA, 2014* 33
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Westat, Inc., 2014* 34
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Repligen Corporation, 2014* 35
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2014* 36
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Natera, Inc., 2014* 37
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hill-Rom Holdings, Inc., 2014* 38
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 39
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 40
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Utah, 2014* 41
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 42
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014* 43
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 44
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 45
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 46
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagoya University, 2014* 47
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by JASMITT Clinical Trial Office, 2014* 48
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 49
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Freiburg, 2014* 50

List of Figures

Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 78

To order this report: Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280946/Spinal-Muscular-Atrophy-SMA-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing be...
Back in February of 2017, Andrew Clay Schafer of Pivotal tweeted the following: “seriously tho, the whole software industry is stuck on deployment when we desperately need architecture and telemetry.” Intrigue in a 140 characters. For me, I hear Andrew saying, “we’re jumping to step 5 before we’ve successfully completed steps 1-4.”
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
As pervasive as cloud technology is -- and as persuasive as the arguments are for using it -- the cloud has its limits. Some companies will always have security concerns about storing data in the cloud and certain high-transaction applications will always be better suited for on-premises storage. Those statements were among the bottom-line takeaways delivered at Cloud Expo this week, a three day, bi-annual event focused on cloud technologies, adoption and associated challenges.
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
SYS-CON Events announced today that Hitachi Data Systems, a wholly owned subsidiary of Hitachi LTD., will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City. Hitachi Data Systems (HDS) will be featuring the Hitachi Content Platform (HCP) portfolio. This is the industry’s only offering that allows organizations to bring together object storage, file sync and share, cloud storage gateways, and sophisticated search an...